Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020

Despite the high cure rate with initial therapy, approximately 10% of Hodgkin lymphoma (HL) patients are refractory to initial treatment, and up to 30% of patients will relapse after achieving initial complete remission. Despite promising initial results of treatment by immune checkpoint inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Simeunovic, Helena, Dickenmann, Martina, Nabergoj, Mitja, Baldomero, Helen, Masouridi‐Levrat, Stavroula, Nair, Gayathri, Schanz, Urs, Passweg, Jacob, Rovo, Alicia, Chalandon, Yves, Rebmann, Ekaterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928795/
https://www.ncbi.nlm.nih.gov/pubmed/36819181
http://dx.doi.org/10.1002/jha2.629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928795/
https://www.ncbi.nlm.nih.gov/pubmed/36819181
http://dx.doi.org/10.1002/jha2.629

Ejemplares similares